PMP22 and hereditary neuropathy with liability to pressure palsies: Unfortunately, we failed to detect any significant variants within the PMP22 regulatory sequence that could be responsible for the gene-dosage effect and the observed clinical variability in the CMT1A/HNPP diseases [20].